MedTrace Logo

Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss

NCT06590779 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2024-09-19

No results posted yet for this study

Summary

Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss. AGA is a polygenetic condition with varying severity, age of onset, and scalp location of hair loss. In men, hair loss typically involves the temporal and vertex region while sparing the occipital region: the characteristic "horseshoe" pattern. Incidence and prevalence of AGA depend on age and race.

Vichy has developed a new cosmetic anti hair loss lotion with the aim of acting on androgenic alopecia. The aim is to improve the efficacy on hair loss of the association of the lotion with finasteride versus finasteride alone.

The primary objective of this investigator-blinded, randomized multi-center study is to quantitatively evaluate, using the phototrichogram method, the efficacy of a lotion associated with finasteride versus finasteride alone on hair growth parameters in male subjects with androgenetic alopecia.

Conditions

Interventions

OTHER

Aminexil® active+ lotion

Aminexil® active+ lotion

OTHER

Finasteride 1mg

Finasteride 1 mg

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER

  • Saint-Louis Hospital, Paris, France

    collaborator OTHER

  • Cosmetique Active International

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
41 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-02
Primary Completion
2025-12-02
Completion
2026-05-02

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590779 on ClinicalTrials.gov